Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07078682 · ClinicalTrials.gov registry record · NA

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

A NA study of Uterine Fibroids and Leiomyoma, sponsored by Zenchi.

Recruiting
Registry status
NA
Development phase
42
Enrollment target
1
Study location

NCT07078682: Recruiting NA study of Uterine Fibroids and Leiomyoma, sponsored by Zenchi.

NCT07078682 is a NA study of Uterine Fibroids and Leiomyoma that is actively recruiting participants, run by Zenchi. The registered enrollment target is 42 participants, below the 240-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07078682, a NA study of Uterine Fibroids and Leiomyoma, is actively recruiting participants, sponsored by Zenchi.

RECRUITING
Registry status
NA
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.

Primary Outcome

Measured as change in menstrual pain and bleeding volume using the validated Uterine Fibroid Symptom Health-Related Quality of Life Questionnaire (UFS-QOL) total and subscale scores.

Interventions

  • DIETARY_SUPPLEMENT Elix Daily Harmony

Study Locations (1)

Nevada

  • Citruslabs - Las Vegas

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2025-08-01
Est. Completion 2026-01
Phase NA
Zenchi

3 total trials

What NCT07078682 shows while recruiting

NCT07078682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 240-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Uterine Fibroids appearing as the primary indexed condition, and to 1 intervention - of which Elix Daily Harmony is the first listed.

NCT07078682 reports a single indexed study location in Nevada.

Frequently Asked Questions

What is clinical trial NCT07078682 about?

NCT07078682 is a clinical study titled "An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms". This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validat...

What is the current status of trial NCT07078682?

This trial is currently recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2025-08-01. Estimated completion is 2026-01.

What conditions does trial NCT07078682 study?

This clinical trial studies the following conditions: Uterine Fibroids, Leiomyoma, Menstrual Pain.

What interventions are being tested in trial NCT07078682?

The interventions under investigation include: Elix Daily Harmony (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07078682?

This trial is sponsored by Zenchi, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07078682 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Fibroids

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07078682's enrollment target sits among peer trials

42 6th of 10 higher than 5 of 10 other Uterine Fibroids trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uterine Fibroids trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07078682, the US trial registry maintained by the National Library of Medicine. NCT07078682 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.